随机临床试验中的时间变化的生物标志物的替代措施
Rui Zhuang1, Fan Xia1, Yixin Wang2
1Department of Biostatistics, University of Washington, Seattle, WA 98195, USA.
概括
研究人员开发了一种新的统计方法来评估临床试验中的代孕标记. 这种方法有助于确定罕见或遥远结果的可靠标记,提高研究效率.
科学领域:
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
- 流行病学 流行病学
背景情况:
- 具有罕见或遥远结果的临床试验需要大样本大小和长时间,这带来了大量的资源和时间挑战.
- 与传统终点相比,使用代用标记物的动机是因为它们有可能更早,更容易地收集.
- 评估和排名潜在的替代标记物具有统计学上的复杂性.
研究的目的:
- 定义对生存设置的治疗效果的概括比例,不依赖于模型假设.
- 为此测量引入一个非参数估计器,它是一致的和异常正常的.
- 提供一种方法来评估由代用标记物介导的治疗效果的比例.
主要方法:
- 在生存分析中对治疗效果的概括比例的定义.
- 为定义的指标开发一种非参数估计程序.
- 理论分析估计器的属性,包括一致性和非对称的正常性.
主要成果:
- 拟议的措施量化了由替代标记物介导的平均治疗效果的比例.
- 在指定的条件下,非参数估计器被证明是一致的,并且在异常情况下是正常的.
- 该方法适用于生存数据,而不需要特定的模型假设.
结论:
- 治疗效果的概括比例提供了一个无模型的方法来评估在生存环境中的代孕标志物.
- 开发的非参数估计器提供了一个统计学上合理的方法来评估标记器效用.
- 这项工作通过利用可靠的代孕标记物,为更有效和可行的临床试验设计做出了贡献.
更多相关视频
09:44Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
Published on: January 29, 2019
10.0K
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
相关概念视频
Comparing the Survival Analysis of Two or More Groups
154
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
154
Introduction To Survival Analysis
184
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
184
Kaplan-Meier Approach
100
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
100
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Censoring Survival Data
64
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
64
Hazard Ratio
91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
91
